Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

NCT06417489 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Combination therapy
DRUG: Sequential treatment group

Sponsor

Peking University First Hospital